United States Patent 12,138,245 (Palovarotene) Scope, Claims, and US Patent Landscape for Fibrodysplasia Ossificans Progressiva (FOP) Flare-Up Dosing
Executive summary
US Patent 12,138,245 is a method-of-use patent focused on weight-banded oral dosing of palovarotene in fibrodysplasia ossificans progressiva (FOP), with a specific flare-up regimen: a “no flare” daily dose, then higher daily dose during flare-up for 28 days, followed by a lower daily dose for at least 56 days (with multiple duration options and symptom definitions). The enforceable claim scope is tightly tied to (i) FOP, (ii) oral palovarotene, (iii) flare vs no-flare periods, (iv) subject body-weight bands, (v) dose amounts, and (vi) timing and duration structures. From a competitive risk standpoint, this patent is designed to cover specific regimen implementation even when the broader active ingredient and general treatment concept may already be covered by earlier palovarotene patents or clinical trial-related compositions/methods.
What does US 12,138,245 claim protect for palovarotene flare-up dosing in FOP?
Core protection theme (what the patent covers):
A stepwise palovarotene oral dosing method to reduce heterotopic ossification in a subject with FOP, where the regimen changes based on flare-up status and body weight.
Structural elements that must be present for infringement (claim 1 template):
- Indication/patient population: “subject with fibrodysplasia ossificans progressiva.”
- Outcome: “reducing heterotopic ossification.”
- Weight band: Claim 1 is for 10 to 20 kg. Claims 7 and 13 expand to 20 to 40 kg and 40 to 60 kg.
- Oral administration.
- Palovarotene (or pharmaceutically acceptable salt).
- No-flare period dosing: daily dose at a lower amount.
- Flare-up period dosing: daily dose at a higher amount for 28 days.
- Post-flare continuation dosing: daily dose after the 28 days for at least 56 days.
- Claim-dependent symptom definitions and treatment duration alternatives: optional claims recite specific flare symptom types and different “at least 56 days” extensions.
Independent claim 1 (10–20 kg band) dosing map
Claim 1 regimen
- No flare: 2.5 mg palovarotene or salt orally daily
- During flare (≥1 flare symptom): 10 mg orally daily for 28 days
- After 28 days: 5 mg orally daily for at least 56 days
Claim 7 (20–40 kg band) dosing map
- No flare: 3 mg daily
- During flare: 12.5 mg daily for 28 days
- After 28 days: 6 mg daily for at least 56 days
Claim 13 (40–60 kg band) dosing map
- No flare: 4 mg daily
- During flare: 15 mg daily for 28 days
- After 28 days: 7.5 mg daily for at least 56 days
Claim-dependent symptom and duration coverage
- Symptom definition (claims 6 and 12 and 18): flare-up symptoms include:
- swelling, pain, erythema, warmth, stiffness, decreased range of motion
- Duration options for the post-flare phase (claims 2–5, 8–11, 14–17):
- “at least 56 days” is concretized into specific alternatives:
- 56 days (baseline)
- 84 days
- 112 days
- 56 days plus an additional 28 days if flare symptoms continue
Practical implication: even if palovarotene use is established, non-infringement generally requires changing at least one of: weight band, dose amounts, 28-day flare window, post-flare minimum 56-day continuation, or the flare symptom-based timing trigger, while still meeting the same therapeutic purpose.
What are the exact claim-dosing windows and how do they affect infringement risk?
Featured snippet answer: The patent requires a three-phase regimen: a lower daily dose during no-flare periods, a higher daily dose during flare for exactly 28 days, then a mid daily dose for at least 56 days, with weight-based dose levels (10–20 kg: 2.5/10/5 mg; 20–40 kg: 3/12.5/6 mg; 40–60 kg: 4/15/7.5 mg).
Regimen timing logic (common structure across the independent claim set)
- Identify a “period when the subject is not experiencing any flare-up symptom.”
- Start daily low-dose palovarotene.
- When at least one symptom appears, switch to daily higher-dose palovarotene for 28 days.
- After the 28 days, switch to daily intermediate-dose palovarotene for at least 56 days.
- Dependent claims permit specific 84- and 112-day endpoints or additional 28-day extension if symptoms persist.
Infringement sensitivity points (where design-arounds typically fail)
- 28 days is explicitly recited for the flare phase in all weight-banded regimens. A competitor regimen using different flare-phase length is the most direct design-around lever, but only if it avoids the literal recited timing and any asserted equivalents.
- Weight bands are explicit. If a regimen is structured using different titration cutoffs or uses a different dosage selection method not captured by the claimed ranges, that can matter.
- Oral administration is explicit. Non-oral delivery routes would avoid literal coverage for this patent, though other palovarotene patents could then be the risk.
- Dose amounts are fixed (2.5, 10, 5; 3, 12.5, 6; 4, 15, 7.5 mg). Small changes are often still “different” in a literal sense, but may invite non-literal theories depending on claim construction.
How broad is US 12,138,245 across weight ranges and patient symptom definitions?
Claim coverage by weight band
- 10–20 kg: Claim 1
- 20–40 kg: Claim 7
- 40–60 kg: Claim 13
This leaves potential gaps outside these bands (for example, <10 kg or >60 kg), at least as to literal coverage under these claims. Dependent claims are tied to the same structure and do not expand weight ranges.
Claim coverage by flare symptom definition
Flare-up symptom list is limited to:
- swelling, pain, erythema, warmth, stiffness, decreased range of motion
The patent ties dosing transition to “during a period when the subject is experiencing at least one flare-up symptom.” If a payer or clinician uses a definition not aligned with the claimed symptoms, it can affect factual infringement but does not change the claimed legal requirement.
What formulations or salts are covered by US 12,138,245 claims?
Plain-language claim scope
- “palovarotene” or a pharmaceutically acceptable salt.
- The claims do not specify a tablet strength, capsule, or formulation excipients in the text provided. The scope is therefore at least as broad as any oral palovarotene presentation that falls within the “palovarotene or salt” concept.
Competitive design implication
- Even if a competitor uses a different oral palovarotene formulation (different dosage form but same drug and regimen), it still risks this method patent because the claim is method/dosing-based, not formulation-based.
What patent estate elements typically surround palovarotene, and where does US 12,138,245 fit?
Without running the full USPTO/Orange Book docket for US 12,138,245’s bibliographic data (which is not included in the prompt), the most reliable landscape conclusion is structural: US 12,138,245 is a dosing regimen patent. In a typical small-molecule orphan drug stack, dosing regimens like this one sit alongside:
- earlier active ingredient patents,
- composition/formulation patents,
- and sometimes biomarker or method-of-treatment patents.
Where this patent is likely strongest
- Litigation against an accused product will often hinge on proving that the provider prescribed the claimed schedule for a patient in the claimed weight band and that the patient was experiencing symptoms that qualify as “flare-up symptoms” under the claim language.
Where it is likely weaker
- If accused dosing differs in any of the key recited elements (flare-phase duration, dose amounts, or weight band selection), the claim can be vulnerable to a strict literal non-infringement position.
How does US 12,138,245 compare with typical palovarotene regimen patterns for design-around?
Regimen comparison checklist for a potential challenger
To reduce risk under US 12,138,245, a regimen would generally need to avoid at least one of:
- Weight-banded dosing at 10–20 kg / 20–40 kg / 40–60 kg with the same dose triplets.
- A flare-up high-dose phase of exactly 28 days.
- A post-flare phase of at least 56 days at the intermediate dose.
- Oral dosing of palovarotene in the described schedule.
Most direct design-around lever: change the flare-up phase length away from 28 days or avoid the precise dose amounts during flare and/or post-flare.
What Orange Book status issues typically matter for this type of method patent?
US 12,138,245 appears to be a US drug patent covering a method of reducing heterotopic ossification via palovarotene dosing. For Hatch-Waxman frameworks, the key practical question is whether it is listed for the referenced NDA/BLA such that generic ANDA filers must address it in an Orange Book certification context.
However, the prompt does not provide:
- the NDA number,
- the Orange Book listing details (expiration, listed patents, exclusivity codes),
- or the reference product naming tied to this patent.
Accordingly, no definitive Orange Book status statement can be made from the provided claim text alone.
What litigation and Paragraph IV generic-entry risk does US 12,138,245 create?
Risk profile
- Because this is a method-of-treatment regimen tied to specific dosing schedules, ANDA filers (and their downstream labels) can attempt to design labeling to avoid instructing the claimed schedule.
- The enforcement risk increases if:
- the accused product’s label or prescribing information effectively teaches the same dosing schedule by default, or
- real-world prescribing is alleged to follow the same regimen despite label differences.
Practical settlement dynamics
Regimen patents often resolve via:
- labeling carve-outs (different duration or dosing),
- or licensing tied to the safest label language to support sales without “core” regimen instruction.
Key takeaways
- US 12,138,245 protects a palovarotene oral flare-management method for FOP that is defined by weight bands and a three-phase dosing schedule (low dose no flare, higher dose during flare for 28 days, then intermediate dose for at least 56 days).
- The claims are dose- and timing-specific: infringement is highly sensitive to the 28-day flare window and the post-flare minimum 56-day continuation.
- Dependent claims add coverage for:
- specific flare symptom types (swelling, pain, erythema, warmth, stiffness, decreased range of motion),
- specific post-flare durations (56/84/112 days and additional 28-day extensions if symptoms persist).
- Competitive design-around would most plausibly rely on changing at least one of: weight-band dose mapping, flare-phase duration, dose amounts, or flare-trigger definition.
FAQs
1) Does US 12,138,245 cover palovarotene use outside 10–60 kg?
Based on the provided claims, literal coverage is tied to weight bands of 10–20 kg, 20–40 kg, and 40–60 kg.
2) Is the flare-up phase duration fixed in the claims?
Yes. In each weight band, the flare-up phase is dosed at the higher amount daily for 28 days.
3) What flare-up symptoms qualify for triggering the higher dose?
The claims list: swelling, pain, erythema, warmth, stiffness, and decreased range of motion, where at least one is present.
4) What happens after the 28-day flare period according to the claims?
The claims require a lower intermediate daily dose for at least 56 days, with dependent claims specifying 56, 84, or 112 days or additional 28-day extensions if symptoms continue.
5) Does the patent require a specific palovarotene salt or a particular dosage form?
The claims cover palovarotene or a pharmaceutically acceptable salt and require oral administration, but they do not specify a particular dosage form in the provided claim text.
References (APA)
- Provided claim text for United States Drug Patent 12,138,245 (user-supplied).
